The aim of our study was to examine the relationship between tumour IKKa expression and breast cancer recurrence and survival. Immunohistochemistry was employed in a discovery and a validation tissue microarray to assess the association of tumour IKKa expression and clinico-pathological characteristics. After siRNA-mediated silencing of IKKa, cell viability and apoptosis were assessed in MCF7 and MDA-MB-231 breast cancer cells. In both the discovery and validation cohorts, associations observed between IKKa and clinical outcome measures were potentiated in oestrogen receptor (ER) positive Luminal A tumours. In the discovery cohort, cytoplasmic IKKa was associated with disease-free survival (p 5 0.029) and recurrence-free survival on tamoxifen (p < 0.001) in Luminal A tumours. Nuclear IKKa and a combination of cytoplasmic and nuclear IKKa (total tumour cell IKKa) were associated with cancer-specific survival (p 5 0.012 and p 5 0.007, respectively) and recurrence-free survival on tamoxifen (p 5 0.013 and p < 0.001, respectively) in Luminal A tumours. In the validation cohort, 
Introduction
Breast cancer is the most common female cancer in the UK and remains the second most common cause of cancer death in women despite earlier detection and improved treatments. Oestrogen receptor (ER)-positive tumours can be effectively treated with tamoxifen and other endocrine therapies, however endocrine resistance remains a major clinical problem. 1 The Gap Analysis Working Group identified molecular mechanisms driving resistance to treatment as one of the top 10 gaps in research that if addressed would make the most clinical impact 2 Studies have demonstrated that 30% of patients with Luminal A disease and 90% of patients with Luminal B exhibit high recurrence scores. 3, 4 The Nuclear Factor kappa B (NF-jB) family of transcription factors has five members (p105/50 (NF-jB1), p100/52 (NF-jB2), p65 RELA, RelB, c-REL) involved in two main pathways, the canonical and non-canonical pathways. 5 Upon activation of the non-canonical NF-jB pathway, the NF-jB-inducing kinase (NIK) phosphorylates IKKa which in turn phosphorylates p100 to identify it for ubiquitination and targeted proteolytic processing subsequently generating p52 and allowing the liberation of active p52/RelB dimmers. 6 These complexes translocate to the nucleus and regulate transcription of a variety of genes important in apoptosis, proliferation, invasion and adaptive immunity. [7] [8] [9] Therefore it is not surprising that studies have demonstrated dysregulation of the non-canonical NF-jB pathway in many solid tumours. 10, 11 More recently the non-canonical NF-jB pathway has been implicated in the development and progression of breast cancer. 12 Oestrogen inhibits the Notch pathway and application of anti-oestrogens result in the activation of Notch 13 and the kinase activity of IKKa has been found to be associated with Notch in the activation of ER-dependent genes. 14 In mice a delay in mammary gland development is observed when p100/52 is overexpressed and these mice developed multiple tumours, 15 however other information is lacking. Our study aims to assess if members of the non-canonical NF-OEB pathway are associated with clinical outcome measures in breast cancer patients.
Materials and Methods

Patient cohorts
This retrospective study used previously constructed tissue microarrays (TMAs) made from formalin-fixed paraffin-embedded tissue (FFPE) blocks retrieved from pathology archives. A consultant pathologist identified tumour rich areas, and three different 0.6 mm 2 cores were lifted from these areas and placed into new blocks. Ethical approval for the use of this tissue was granted by the Research Ethics Committee of the North Glasgow University Hospitals NHS Trust (NHS GG&C rec no 10/50704/60).
The discovery cohort TMA included 362 breast cancer patients presenting with invasive ductal breast cancer in the West of Scotland (at Glasgow Royal Infirmary, Glasgow Western Infirmary and Stobhill Hospital), between 1995 and 1998. Patients were excluded if follow-up was incomplete or tumour tissue was insufficient. Clinico-pathological data available included age, tumour grade, tumour size, lymph node status, therapy, ER, PgR and HER2 status and Ki67 proliferation index. Information on inflammatory infiltrate and tumour microenvironment had previously been established for the cohort. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] IHC for IKKa was performed on a validation cohort of ER-positive patients. This TMA and clinical database included 266 ER-positive patients presenting with invasive ductal breast cancer between 1980 and 1995 from Glasgow Royal Infirmary. Clinico-pathological data available included age, tumour grade, tumour size, lymph node status, therapy, PgR and HER2 status and Ki67 proliferation index. [28] [29] [30] [31] All patients in this cohort were treated with adjuvant tamoxifen.
Immunohistochemistry
Immunohistochemistry (IHC) was performed to assess protein levels of RelB, NIK and IKKa; components of the non-canonical NF-jB pathway. TMA sections (2.5 mm thick) were dewaxed by immersion in xylene and rehydrated through a series of graded alcohols. Heat induced antigen retrieval was performed in a solution of citrate buffer pH6. Tissue was then incubated in 3% (v/v) hydrogen peroxide before non-specific binding was blocked by incubation in either 5% (v/v) normal horse serum solution (Vector Laboratories; IKKa, RelB) or 13 casein solution (Vector Laboratories; NIK). Slides were then incubated in primary antibody overnight at 48C at optimal concentration of antibody diluted in antibody diluent (Dako, Copenhagen, Denmark). The primary antibodies and concentrations used are as follows: antiRelB (#4954, Cell Signaling) was used at 1:75, anti-NIK (S2622, Epitomics) at 1:250 and anti-IKKa (GWB-662250, Genway, San Diego, USA) at 1:1,000. Staining was developed using EnVision TM (Dako) and 3,3 0 -diaminobenzidine (DAB, Vector Laboratories). Harris Haematoxylin counterstaining was performed and tissue was dehydrated and mounted using DPX. Supplementary Figure 1 provides examples of high and low IKKa staining. Antibodies were validated by western blotting and IHC, for the anti-IKKa antibody, a single band of the predicted molecular weight (85 kDa) was observed on a western blot. Cells were pretreated with 200 nM siRNA against either IKKa or IKKb to check specificity for IKKa. A reduction in expression was observed in IKKa silenced but not IKKb silenced cells as assessed by western blotting of cell lysates and IHC of cell pellets ( Supplementary Fig. 2 ).
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) at x20 magnification and visualization was carried out using Slidepath Digital Image Hub, version 4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK). Protein expression was assessed using the weighted histoscore method [LB] , with a second independent observer [JE] scoring 10% of cores and the interclass corRelation coefficient (ICCC) calculated to ensure no observer bias. 32 Cytoplasmic and nuclear expression were calculated separately.
Cell culture
MCF7 (ER-positive) and MDA-MB-231 (ER-negative) breast cancer cells were routinely cultured in 5% CO 2 at 378C in Dulbecco's Modified Eagle Medium (DMEM, Life Technologies, Paisley, UK) with 10% (v/v) Fetal Bovine Serum (FBS, SigmaAldrich, Gillingham, UK), 10 Units/ml Penicillin/Streptomycin (Life Technologies) and 13 GlutaMAX TM (Life Technologies).
Ligand exposure
Cells were seeded in 12-well plates at 1 3 10 5 cells per well and once 70% confluent were rendered quiescent by incubation in serum free media for 24 hr and exposed to 20 ng/ml What's new? The dysregulation of signaling pathways involving members of the nuclear factor kappa B (NF-jB) family is a significant feature in breast cancer. Of particular consequence is aberrant activation of the noncanonical NF-jB pathway, which is associated with activity of the inhibitor of NF-jB kinase a (IKKa). In our study, increased IKKa levels were associated with reduced cancer-specific survival and reduced recurrence-free survival in oestrogen receptor (ER-)-positive breast cancer patients treated with tamoxifen. In ER-positive breast tumour cells, IKKa silencing triggered apoptosis and decreased cell viability. According to the findings, IKKa is a possible target in endocrine-treated breast cancer.
lymphotoxin a 1 b 2 (LTx, Sigma-Aldrich) for 4 hr, 8 hr and 24 hr to stimulate the non-canonical pathway.
Western blotting
After exposure to the LTx or siRNA, cells were lysed in preheated Laemmli's sample buffer and SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was performed using resolving gels. Proteins were then transferred to nitrocellulose membranes by electrophoretic blotting in wet conditions and non-specific binding blocked by incubation in a solution of 3% (w/v) BSA in NaTT buffer. Membranes were incubated overnight, either at room temperature or 48C, in primary antibody specific to the target protein diluted to optimal concentration in NaTT buffer containing 0.3% (w/v) BSA. Antibodies and dilutions used were as follows: IKKa (1:3,500, OP133, Calbiochem), p100/52 (1:3,000, 05-361, Millipore, Walford, UK), phospho-p100 (1:2,000, #4810, Cell Signaling). b-tubulin was used (1:5,000, ab21058, Abcam, Cambridge, UK) as a loading control.
Membranes were washed for 1hr 30 min with NaTT, changed every 15 min, and then were incubated in secondary HRP-conjugated antibody (either rabbit or mouse, depending on primary antibody) diluted 1:10,000 for 1 hr 30 min and then washed again as per previous. Enhanced chemiluminescence (ECL) reagent (1:1 mixture of solution 1 [1M Tris pH8.5, 250 mM luminol, 250 mM p-cymuric acid and water] and solution 2 [1M Tris pH8.5, 0.19% H 2 O 2 and water]) was used to develop and X-ray films developed using an X-OMAT machine (Kodak, Rochester, USA) or the SynGene imaging system. Images were quantified using ImageJ with protein expression normalized to the b-tubulin loading control and expression compared to untreated cells, calculated as fold change to control. Statistical analysis was performed using a one-way ANOVA with Bonferroni correction and Dunnett's test to compare to control levels.
siRNA-mediated silencing of IKKa
To observe the impact of loss of cellular IKKa expression on cellular viability, MCF7 and MDA-MB-231 cells were transfected with ON-TARGETplus siRNA (Thermo Scientific) against sequences for IKKa (CHUK, #J-003473-09) and non-targeting sequence (NT) was used as a negative control (Non-targeting #1, #D-001810-01-20). Lipofectamine
V R (Life Technologies) was used to deliver the siRNA to the cells. After 6 hr media was replaced with normal DMEM containing 10% (v/v) FCS and after 48 hr protein lysis and analysis via Western blotting was performed, or a functional assay was applied to assess apoptosis or viability.
Apoptosis and cell viability assays
We employed the use of RNA interference to observe the effect a decrease in expression of IKKa had on cell growth and viability in MCF7 and MDA-MB-231 cells. MCF7 and MDA-MB-231 cells were transfected with 200 nM NT siRNA or 200 nM IKKa siRNA. These cells were then seeded for use in apoptotic assays, wst-1 assays and western blotting. The western blot was used to ensure a decrease in expression of IKKa had been achieved in the cells used for the apoptotic and cell viability assays. Forty eight hours post treatment, apoptotic and cell viability assays were performed and cells lysed for western blot analysis. This method ensured that the cells used in both the assays were from the same population. Cells were assessed for apoptosis levels using a Cell Death Detection enzyme-linked immunosorbent assay kit (Roche) and for cell viability using the water-soluble tetrazolium salt (WST-1) reagent (Roche). Cells were seeded in 96-well plates at a density of 5 3 10 3 cells/well in 100 ll of standard culture medium. Once a confluence of 60-70% was reached cells were exposed to siRNA for 48 hr and the assays then performed following manufacturer's instructions. Assays were performed in triplicate and error bars representing standard deviation added to graphs.
Cell viability via xCELLigence
The xCELLigence machine (ACEA Biosciences, San Diego, CA) was used to display cell growth and viability in real time following silencing of IKKa. With this method, measurements are continuously sent to the computer, allowing for real time growth curves to be plotted using "Cell Index" which represents the number and viability of the cells. Cells were seeded in a 96-well E-plate TM (ACEA Biosciences) at 3 3 10 3 cells/well with 200 ll of media in each well, grown for two days to ensure log phase growth before treatment with siRNA and after 72 hr graphs showing cell index over time were drawn.
Taqman low density arrays (TLDA)
As the biggest effect on phenotypic output was observed for apoptosis in ER-positive MCF7 cells, 384 TLDA gene signature apoptosis arrays containing 93 genes Related to apoptosis and 3 candidate endogenous controls were employed to investigate the change in gene profile following siRNA-mediated silencing (NT or IKKa). After 48 hr silencing incubation, the media was replaced with serum free media for 12 hr to rendered quiescent followed by LTx stimulation for 12 hr. Thus, the total time for silencing and LTx treatment was 72 hr. RNA was extracted using an RNeasy mini kit following manufacturer's protocol with DNase digestion performed on the column (Qiagen). Preparation of cDNA and RT-PCR were performed using TaqMan RT-PCR methodology and reagents (Perkin-Elmer Applied Biosystems). TLDA gene arrays containing 93 genes and 3 candidate endogenous controls were employed to determine if IKKa silencing induced change in expression of genes (Supplementary Table 1 ). Each sample from three independent silencing experiments on MCF7 cells was run in duplicate. All results were analyzed simultaneously by RQ Manager Software (ABI, UK) and the threshold cycle (Ct) values for the genes of interest were calibrated against 18S Ct (dCt).
Statistical analysis
Statistics were performed using IBM SPSS version 21. Kaplan-Meier curves were constructed for cancer-specific survival and the log rank test was employed to compare high and low expression. Hazard ratios were calculated using Cox regression with 95% confidence intervals. Cox regression multivariate analysis was also performed with the inclusion of known predictive factors. Inter-Relationships between variables were assessed using contingency tables with the chisquared test for trend as appropriate. Values of p < 0.05 were considered statistically significant. Statistical analysis for Western blots, apoptosis and cell viability assays was performed using a one-way ANOVA with Bonferroni correction and Dunnett's test. p-Values were considered significant if p < 0.05 and highly significant if p < 0.001. TLDA card raw data were analyzed using Quantstudio 7 with the following settings: 1) automatic baseline 2) threshold 5 0.2. Ct values over 32 were defined as undetectable. Significant changes in gene expression were defined with a p-values boundary of 0.05. Results are presented as a volcano plot.
Results
IKKa expression is associated with poor prognosis in breast cancer
Discovery cohort. A total of 362 patients who presented with invasive ductal breast cancer were included in the study. ER, PgR, HER2 and Ki67 status were available allowing determination of the tumour subtype, 46% (165) of patients had Luminal A disease (ER or PgR-positive, HER2-negative and low Ki67 <14%), 22% (81) had Luminal B disease (ERor PgR-and HER2-positive or ER, PgR and high Ki67 (>14%)), 20% (72) had triple negative disease (ER-, PgRand HER2-negative) and 10% (38) had HER2 enriched (ERand PgR-negative, HER2-positive). We were unable to define subtype in 2% (6) of cases due to missing data.
Expression of IKKa was observed in the tumour cell cytoplasm and nucleus (median expression 100, interquartile range 69-140 and median expression 126, interquartile range 73-115, respectively). NIK expression was observed in the tumour cell cytoplasm (median expression 100, interquartile range 69-140) and RelB expression was observed in the tumour cytoplasm and the nucleus (median expression 113, interquartile range 90-146 and median expression 0, interquartile range 0-7, range 0-190, respectively). No correlations were observed between NIK expression and expression of IKKa in any cellular location investigated. Expression of cytoplasmic IKKa correlated with cytoplasmic and total tumour cell RelB (p 5 0.005 and p 5 0.003, respectively), nuclear IKKa correlated with nuclear and total tumour cell RelB (p < 0.001 and p < 0.001, respectively) and total tumour cell IKKa correlated with cytoplasmic, nuclear and total tumour cell RelB expression (p 5 0.010, p 5 0.004 and p < 0.001, respectively).
Eighty four patients had local or distant recurrence, the median follow-up of survivors was 164 months with 76 cancer-associated deaths and 77 non-cancer deaths. Expression of NIK or RelB was not associated with cancer-specific survival, disease-free survival or recurrence-free survival on tamoxifen, in the full patient cohort or when stratified by tumour subtype (Tables 1 and 2 ).
High cytoplasmic IKKa was not associated with cancerspecific survival in the full cohort (Table 1) , however was significantly associated with shorter disease-free survival (Table  1 ) (p 5 0.045) and recurrence-free survival on tamoxifen (Table 1 ) (p 5 0.003). 5 year disease-free survival was reduced from 88% (low) to 79% (high) (p 5 0.039) and recurrencefree survival on tamoxifen was reduced from 73% (low) to 25% (high) (p 5 0.019).
When stratified by tumour subtype, high cytoplasmic IKKa expression showed a non-significant trend towards shorter cancer-specific survival ( Fig. 1a ; p 5 0.076), a significant association with shorter disease-free survival ( Fig. 1b ; p 5 0.029) and a significant association with shorter recurrence-free survival on tamoxifen ( Fig. 1c ; p < 0.001) in Luminal A tumours. 5 year disease-free survival was reduced from 99% (low) to 89% (high) (p 5 0.011) and recurrencefree survival on tamoxifen was reduced from 94% (low) to 30% (high) (p < 0.001).
The relationship between cytoplasmic IKKa and tumour characteristics was examined. High expression of cytoplasmic IKKa was associated with tumour size (p 5 0.032), tumour grade (p 5 0.009), ER-positive disease (p 5 0.002), HER2-positive disease (p 5 0.023) and tumour subtype (p < 0.001). When associations with the tumour microenvironment were investigated, cytoplasmic IKKa was not significantly associated with tumour stroma percentage (TSP) or tumour budding. However an association was observed with necrosis (p 5 0.009) and local inflammatory cell infiltrate as assessed by Klintrup-M€ akinen grade (p 5 0.005).
High nuclear IKKa was not associated with cancer-specific survival, disease-free survival or recurrence-free survival on tamoxifen in the full cohort (Table 1 ). However when stratified by tumour subtype, high nuclear IKKa expression showed a significant association with shorter cancer-specific survival ( Fig. 1d ; p 5 0.012), a non-significant trend towards shorter disease-free survival ( Fig. 1e ; p 5 0.066) and a significant association with recurrence-free survival on tamoxifen ( Fig. 1f ; p 5 0.013) in Luminal A tumours. 10 year cancer-specific survival was reduced from 97% (low) to 87% (high) (p 5 0.013) and recurrence-free survival on tamoxifen was reduced from 100% (low) to 55% (high) (p 5 0.015).
The relationship between nuclear IKKa and tumour characteristics was examined. High expression of nuclear IKKa was associated with tumour grade (p 5 0.014), ER-positive disease (p 5 0.047), tumour subtype (p 5 0.042) and patient survival (p 5 0.008). When associations with the tumour microenvironment were investigated, nuclear IKKa was not significantly associated with TSP or tumour budding. However an association was observed with local inflammatory cell infiltrate as assessed by Klintrup-M€ akinen grade (p 5 0.016) and density of CD8 To examine the relationship of cancer-specific survival and total tumour cell expression of IKKa, a cumulative prognostic score of cytoplasmic and nuclear IKKa was examined (total tumour cell IKKa). Patients with both high cytoplasmic and nuclear expression were classified as the high expression group and patients with either low cytoplasmic or nuclear expression were classified as the low expression group. High expression of total tumour cell IKKa, was not associated with shorter cancerspecific survival or disease-free survival in the full cohort, but was associated with recurrence-free survival on tamoxifen (Table 1 ; p 5 0.011). Recurrence-free survival on tamoxifen was reduced from 79% (low) to 54% (high) (p 5 0.029).
When stratified by tumour subtype, high total tumour cell IKKa expression showed a significant association with shorter cancer-specific survival ( Fig. 1g ; p 5 0.007), shorter disease-free survival ( Fig. 1h ; p 5 0.013) and recurrence-free survival on tamoxifen (Fig. 1i) (p < 0.001) in Luminal A tumours. 10 year cancer-specific survival was reduced from 96% (low) to 83% (high) (p 5 0.006), 5 year disease-free survival was reduced from 99% (low) to 86% (high)( p 5 0.001) and recurrence-free survival on tamoxifen was reduced from 94% (low) to 30% (high) (p < 0.001).
High expression of total tumour cell IKKa was only associated with density of CD8 1 T-lymphocytes (p 5 0.034) and not with any other tumour or microenvironment characteristics.
In Luminal A tumours, when cytoplasmic, nuclear and total tumour cell IKKa were entered into a multivariate model using a backwards conditional method with clinic-pathological parameters, only nuclear IKKa remained independently associated with cancer-specific survival (HR 5 9.4, 95% CI 5 2.02-22.67, p 5 0.004, Table 2 ). 
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Validation cohort. As the strongest associations were observed between IKKa and clinical outcome measures in patients with Luminal A tumours in the discovery cohort, this was investigated in an independent ER-positive validation cohort. A total of 266 patients who presented with ERpositive invasive ductal breast cancer were included in the study. ER, PgR, HER2 and Ki67 status were available for these patients allowing us to determine the tumour subtype. 76% (201) of patients had Luminal A disease and 21% (56) had Luminal B disease. We were unable to define subtype in 3% (9) of cases due to missing data.
Expression of IKKa was observed in the tumour cell cytoplasm within a similar range to that observed for the ERpositive tumours in the discovery cohort (discovery cohort: median expression, 96 interquartile range 61-130, validation cohort: median expression 96, interquartile range 73-120). However expression in the nucleus between the cohorts was not similar (discovery cohort: median expression 133, interquartile range 80-180, validation cohort: median expression 33, interquartile range 15-60).
Seventy four patients had local or distant recurrences, the median follow-up of survivors was 96 months with 69 cancer-associated deaths and 58 non-cancer deaths. As was previously observed in discovery cohort, high cytoplasmic IKKa was not associated with cancer-specific survival and was significantly associated with shorter disease-free survival (Fig 2a; p 5 0.024) and recurrence-free survival on tamoxifen ( Fig. 2b ; p 5 0.038) in the validation cohort.
When stratified by tumour subtype, high cytoplasmic expression of IKKa showed a significant association with shorter cancer-specific survival ( Fig. 2c ; p 5 0.023), shorter disease-free survival ( Fig. 2d ; p 5 0.002) and recurrence-free survival on tamoxifen ( Fig. 2e ; p 5 0.009) in Luminal A tumours. 10 year cancer-specific survival was reduced from 80% (low) to 62% (high) (p 5 0.005), 5 year disease-free survival was reduced from 87% (low) to 64% (high) (p 5 0.004) and recurrence-free survival on tamoxifen was reduced from 84%(low) to 66% (high) (p 5 0.027).
High expression of cytoplasmic IKKa was associated with tumour grade (p 5 0.009) as previously observed for discovery cohort. We were unable to assess associations with IKKa and the tumour microenvironment as these parameters were not available for analysis for the validation cohort.
In Luminal A tumours, when cytoplasmic IKKa was entered into a multivariate model using a backwards conditional method with size, grade and nodal status, parameters, cytoplasmic IKKa remained independently associated with cancer-specific survival (HR 5 2.03, 95% CI 5 1.06-3.87, p 5 0.031).
In the validation cohort nuclear IKKa and total tumour cell IKKa were not associated with cancer-specific survival, disease-free survival or recurrence-free survival on tamoxifen in the full cohort or in Luminal A tumours.
IKKa silencing is associated with reduced cell viability and induction of apoptosis in ER-positive breast cancer cells
We observed that IKKa expression is associated with poor prognosis in breast cancer patients, and this is potentiated in the ER-positive Luminal A subtype. Therefore, the next aim of the study was to establish if IKKa could offer a novel therapeutic target for treatment of breast cancer. MCF7 cells were chosen to represent ER-positive breast tumours and MDA-MB-231 was chosen to represent ER-negative breast tumours.
Both cell lines were treated with lymphotoxin (LTx), a ligand known to stimulate the non-canonical NF-jB 
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pathway. In ER-positive MCF7 cells LTx significantly increased p52 expression on average 2.1-fold after 24 hr (Fig.  3a) (p 5 0.049). An increase in p100 phosphorylation was clearer with an increase at 8 hr LTx exposure (Fig. 3a) (p 5 0.024) and peak expression at 24 hr exposure with an average 8.8-fold increase compared to untreated MCF7 cells (Fig. 3a) (p 5 0.005). In ER-negative MDA-MB-231 cells constitutive expression of phospho-p100 was observed, with little difference between control and cells exposed to LTx (Fig. 3a) . In addition, no significant increase in p52 was evident with LTx exposure at any time point (Fig. 3a) .
Using a lipofection based method, siRNA was delivered to the cells to reduce expression of IKKa. After 48 hr incubation siRNA targeted to IKKa effectively reduced expression of IKKa at all concentrations in both cell lines (Fig. 3b) .
MCF7 and MDA-MB-231 cells were transfected with 200 nM IKKa siRNA, as well as non-targeting (NT) siRNA, and 48 hr post treatment the apoptosis assay was performed. Serum starvation, which induces apoptosis, was used as an additional control. ER-positive MCF7 cells treated with NT siRNA did not show a significant difference in apoptosis when compared to untreated control cells (Fig. 3c ) (p 5 0.992). A significant increase was observed in levels of apoptosis when cells were treated with siRNA to silence expression of IKKa (Fig. 3c) (p 5 2.5 3 10 
25
). ER-negative MDA-MB-231 cells treated with either NT or IKKa siRNA did not show a significant difference in apoptosis when compared to untreated control cells (Fig. 3c) (both p 5 1.0) .
Cell viability was also assessed in both MCF7 and MDA-MB-231 cells following siRNA-mediated silencing of IKKa for 48 hr. In MCF7 cells treated with NT siRNA, cell viability was not significantly different from untreated control cells ( Fig. 4a; p 5 0.550) . A decrease in cell viability was observed when cells were treated with siRNA to silence expression of IKKa ( Fig. 4a; p 5 0.001) . In MDA-MB-231 cells, cell viability was not significantly different in cells treated with NT or IKKa siRNA in comparison to untreated control cells ( Fig.  4a ; p 5 0.952 and P 5 0.889, respectively).
Cell viability was also measured using the xCELLigence platform. In MCF7 ER-positive cells NT siRNA did not appear to be different from that observed for untreated cells but siRNA to silence expression of IKKa reduced cell viability (Fig. 4b) . In MDA-MB-231 cells neither NT nor IKKa siRNA displayed any difference in cell viability compared to untreated cells (Fig. 4b) .
As the associations with cell viability were only observed in ER-positive MCF7 cells and the strongest association being for apoptosis, TLDA apoptotic signature gene cards were employed to examining changes in gene expression as a result of IKKa silencing in these cells. The results are displayed as a volcano plot (Fig. 4c) . Fourteen genes induced by LTx treatment were noted to change significantly in response to IKKa siRNA (CHUK, BAK1, BBC 3, CRADD, BCL 10, RIPK2, TNFSF10, FAS, BIRC3, CASP8, NFKBIA, CASP3, CFLAR and TNFRSF2) (Fig. 4c) . CHUK (IKKa) was used as an internal control to demonstrate that silencing had been effective. The pro-apoptotic genes BAK and BBC3 showed the greatest fold change increase across the 3 experiments.
Discussion
In our study, immunohistochemistry was employed to assess expression/levels of NIK, RelB and IKKa in a discovery cohort and establish associations with clinico-pathologic parameters. NIK and RelB were not associated with cancerspecific survival, disease-free survival or recurrence-free survival on tamoxifen in the full cohort or when stratified by tumour subtype as determined by ER, Pgr, HER2 and Ki67 status. Breast cancer can be stratified into four molecular subtypes (Luminal A, Luminal B, triple negative and HER2 enriched) bases on gene profiling, however it is now widely accepted that tumours can now be classified into tumour subtypes using a panel of 4 biomarkers (ER, PgR, Ki67 and HER2), and although not true representatives of molecular subtype, do represent tumour subtypes with different patient prognosis, therefore in our study although when tumour subtype is referred to it is on the basis of ER, PgR, HER2 and Ki67 status and not molecular subtypes as defined by gene profiling.
In our study although NIK and RelB are not associated with patient recurrence or survival, in contrast levels of IKKa expression were associated with disease-free survival in the full cohort and when the cohort was stratified by subtype. Associations between patient outcome measures were completely negated in the Luminal B subtype, but potentiated in the ER-positive Luminal A subtype. Luminal A subtype is the most common subtype in this patient cohort, therefore it could be possible that this observation is due to the Luminal Figure 3C and also for the cells used in the wst-1 assays Figure 4A .
A group being the only appropriately powered subtype in this cohort. However no trends were observed for patients with Luminal B, triple negative or HER2 enriched subtypes, providing weight to the argument that the associations observed were only observed in patients with Luminal A tumours.
As it is only IKKa that is associated with patient outcome and not expression levels of NIK or RelB, it is probable that activation status of NIK and RelB are required to be measured to demonstrate activation of the pathway, however as there are inherent problems associated with phosphorylated antibodies we propose IKKa is a more robust marker to be employed. An alternative explanation is IKKa has a role independent of the non canonical pathway, however our study has no conclusive evidence to support this theory. Recently work in colorectal cancer and cutaneous squamous cell carcinoma has demonstrated a role for IKKa independent of the non-canonical NF-jB pathway 10, [33] [34] [35] and this been suggested to be via a truncate form of IKKa (p45 IKKa) that is constitutively active and specifically resides in the nucleus. 10 In the discovery cohort, when Luminal A tumours were considered only nuclear IKKa remained independently associated with cancer-specific survival. This suggests that nuclear IKKa expression had a stronger predictive power than total tumour cell IKKa, and could be due to detection of the truncated activated form of IKKa. However, this observation was not upheld in the validation cohort, as it was only cytoplasmic IKKa that remained associated with prognosis, suggesting it is more likely that cytoplasmic IKKa is a better marker of non canonical pathway activation, and nuclear truncated IKKa does not play a strong role.
Taken in combination, these results suggest irrespective of cellular location that IKKa plays an important role in the progression of breast cancer, as cytoplasmic, nuclear and total tumour cell expression of IKKa were all associated with clinical outcome measures in patients with Luminal A disease.
Due to the associations of IKKa expression with clinical outcome measures in patients with Luminal A disease, IKKa was assessed in a second validation cohort, of 266 women with ER-positive breast cancers, all of whom received tamoxifen therapy. This cohort, provided greater power for investigating associations with recurrence-free survival on tamoxifen. In the validation cohort, cytoplasmic IKKa expression levels were observed at very similar levels to that of the discovery cohort. However nuclear IKKa expression in the validation cohort was at a much lower level than that of the discovery cohort. The reason for this was unclear as the same antibody and immunohistochemical protocol were employed across both studies. One possible explanation is that the second cohort was older therefore may have been subject to different fixation methods or storage or that nuclear IKKa is more prone to degradation than cytoplasmic IKKa. As a result of the differing nuclear expression levels, the same cut offs for nuclear IKKa to determine high and low expression could not be employed across both cohorts. Even when median values of nuclear IKKa from the validation cohort were used, the results obtained in the discovery cohort were not replicated.
In contrast we were able to validate the results observed in the discovery cohort for cytoplasmic IKKa expression in the validation cohort. Once again cytoplasmic IKKa was observed to be associated with disease-free survival and recurrence-free survival on tamoxifen in the full validation cohort, and this observation was potentiated in patients with Luminal A disease. Taken together the results from both cohorts suggest that cytoplasmic IKKa is a more robust marker than nuclear IKKa and may be employed as a prognostic marker in Luminal breast cancer to predict patients likely to develop resistance to tamoxifen or IKKa targeted therapies.
Preliminary experiments were performed to investigate if targeting IKKa offered a possible therapeutic target in breast cancers. IKKa expression was suppressed using siRNA and cell viability assessed. Decreased cell growth and viability can reflect either a reduction in proliferation rates or an increase in apoptosis, or a combination of both mechanisms. Cell viability was measured through various methods including assessment of apoptosis using an ELISA, viability using a WST-1 assay, realtime growth and viability using xCELLigence. The effect of silencing IKKa on phenotypic outputs was examined in both ER-positive MCF7 cells and ER negative MDA-MB-231 cells, to establish if a difference was observed between ER status as was observed in the patient tissue samples. In keeping with results from the clinical specimens, IKKa silencing only had an impact in ER-positive MCF7 breast cancer cells and not on ERnegative MDA-MB-231 cells. In addition, gene card experiments demonstrated that reducing IKKa expression had a significant impact on increased expression of genes associated with induction of apoptosis, in particular BAK1 and BBC3. This is in keeping with previous reports that demonstrate that both BAK1 and BBC3 are associated with prognosis and or response to therapy in breast cancer. [36] [37] [38] It therefore appears that IKKa selective inhibitors would be most beneficial to patients with ER-positive tumours and may function via induction of apoptosis and inhibition of proliferation. Studies from the literature demonstrate that IKKa is involved in regulation of oestrogen-dependent genes such as cyclin D1 and c-myc, resulting in increased proliferation. 6 However, future studies in a large panel of ER positive and ER negative cell lines are required to confirm this observation. Future studies should also investigate impact of tamoxifen treatment and resistance to tamoxifen in cell line studies.
The results from both the tissue and in vitro work from our study demonstrate that IKKa is associated with regulation of ER-positive breast cancer, suggesting inhibitors of IKKa would be beneficial for breast cancer patients. Exploiting IKKa as a target may offer additional therapeutic options following development of endocrine resistance.
2 Additional thorough investigation, including both larger tissue studies and mechanistic work, is required to further elucidate the role of IKKa in the progression of breast cancer, though involvement of IKKa in breast cancer recurrence is clearly apparent. Once novel compounds are found to be selective and efficient in preclinical models, inhibitors of IKKa may therefore provide a promising therapeutic approach in the future for breast cancer, particularly in patients who develop endocrine resistance.
